Recently, the therapeutic use of GLP-1R agonists has been suggested in PD because of this receptor’s important role in the prevention of DA neuron loss and microglia-mediated neurotoxic A1 reactive astrocytes [117]. This evidence concerns the gene GLP1R and Parkinson disease.